Intellectual Property Strategy
Basic Policy on Intellectual Property
1. Contribute toward the improvement of people's health and progress in society
The ASKA Pharmaceutical Holdings Group positions its intellectual property activities as one of the essential elements of its business development as a pharmaceutical company, and strategically develops them based on its corporate philosophy of “Contribute toward the improvement of people's health and progress in society through the development of innovative products”. We will maximize the value of our intellectual property rights by formulating and promoting an intellectual property strategy that globally develops activities related to intellectual property, including patent rights, utility model rights, design rights, and trademark rights.
2. Protection and utilization of intellectual property
The Group will appropriately protect and manage intellectual property created through research and development activities, and will actively utilize intellectual property to enhance corporate value.
3. Compliance with laws and respect for the intellectual property rights of third parties
The Group will comply with laws and regulations related to intellectual property and respect the valid intellectual property rights of third parties. The Group will conduct its business in fair competition without infringing on intellectual property rights.
Intellectual property activities
The Group conducts various intellectual property activities in accordance with its basic policy on intellectual property.
Formulation and Promotion of Intellectual Property Strategy
The Company Group aims to deliver high-value pharmaceuticals and products that contribute to people's health and animal health. In order to formulate an intellectual property strategy aimed at enhancing the value of drugs and products, the Group examines its own intellectual property and that of other companies from a variety of perspectives, and considers ways to discover and utilize its own intellectual property.
We strategically apply for and obtain patents, utility model rights, design rights, trademark rights, etc. for intellectual property created during the research and development process, and by appropriately protecting and utilizing this intellectual property, we are able to increase the value of our drugs and products.
We also take great care to ensure that our drugs, products and intellectual property do not infringe on the rights of third parties.
Improving product value through user-focused business activities
The Group develops its business with the starting point of “what kind of value can we provide” to patients, medical professionals, and livestock producers. In this context, we are developing our research and development activities by strengthening our partnerships with external parties as well as utilizing our own know-how, so that we can receive feedback from patients and other stakeholders that our drugs and products have improved their quality of life (QOL).
We aim to further improve the value of our products by appropriately protecting and utilizing the intellectual property that we collect and create through these initiatives.
Co-creation of intellectual property through open innovation
The Group is promoting open innovation of intellectual property through industry-government-academia collaboration in order to deliver valuable drugs and products to patients as quickly as possible. In areas where it would be difficult for the Group to develop on its own, we are creating new and valuable drugs and products by attempting to exchange technology and collaborate with external parties without limiting the type of industry, nationality, or scale.
In addition, in the area of women's healthcare, which is one of our strengths, we are working to create further intellectual property value by deploying our own intellectual property to partner companies.
In this way, we are aiming to strategically co-create intellectual property.